166 related articles for article (PubMed ID: 25179096)
1. Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.
Rubio-Terrés C; Rubio-Rodríguez D; Baca-Baldomero E
Actas Esp Psiquiatr; 2014; 42(5):242-9. PubMed ID: 25179096
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
3. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
[TBL] [Abstract][Full Text] [Related]
7. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.
McKendrick J; Cerri KH; Lloyd A; D'Ausilio A; Dando S; Chinn C
J Psychopharmacol; 2007 Aug; 21(6):588-96. PubMed ID: 17050661
[TBL] [Abstract][Full Text] [Related]
9. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
Dilla T; Prieto L; Ciudad A; Sacristán JA
Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Fajutrao L; Paulsson B; Liu S; Locklear J
Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903
[TBL] [Abstract][Full Text] [Related]
14. Cost-saving effects of olanzapine as long-term treatment for bipolar disorder.
Zhang Y
J Ment Health Policy Econ; 2008 Sep; 11(3):135-46. PubMed ID: 18806303
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy.
Qiu Y; Christensen DB; Fu AZ; Liu GG
Curr Med Res Opin; 2009 Feb; 25(2):351-61. PubMed ID: 19192979
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Pharmacoeconomics; 2012 Jun; 30(6):513-30. PubMed ID: 22591130
[TBL] [Abstract][Full Text] [Related]
17. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.
Zhu B; Tunis SL; Zhao Z; Baker RW; Lage MJ; Shi L; Tohen M
Curr Med Res Opin; 2005 Apr; 21(4):555-64. PubMed ID: 15899104
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of paliperidone extended release in Spain.
Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
[TBL] [Abstract][Full Text] [Related]
19. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Perlis RH
Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.
Caresano C; Di Sciascio G; Fagiolini A; Maina G; Perugi G; Ripellino C; Vampini C
Adv Ther; 2014 Aug; 31(8):873-90. PubMed ID: 25055791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
